ABSTRACT
De novo guanine biosynthesis is an evolutionarily conserved pathway that creates sufficient nucleotides to support DNA replication, transcription, and translation. Bacteria can also salvage nutrients from the environment to supplement the de novo pathway, but the relative importance of either pathway during Staphylococcus aureus infection is not known. In S. aureus, genes important for both de novo and salvage pathways are regulated by a guanine riboswitch. Bacterial riboswitches have attracted attention as a novel class of antibacterial drug targets because they have high affinity for small molecules, are absent in humans, and regulate the expression of multiple genes, including those essential for cell viability. Genetic and biophysical methods confirm the existence of a bona fide guanine riboswitch upstream of an operon encoding xanthine phosphoribosyltransferase (xpt), xanthine permease (pbuX), inosine-5′-monophosphate dehydrogenase (guaB), and GMP synthetase (guaA) that represses the expression of these genes in response to guanine. We found that S. aureus guaB and guaA are also transcribed independently of riboswitch control by alternative promoter elements. Deletion of xpt-pbuX-guaB-guaA genes resulted in guanine auxotrophy, failure to grow in human serum, profound abnormalities in cell morphology, and avirulence in mouse infection models, whereas deletion of the purine salvage genes xpt-pbuX had none of these effects. Disruption of guaB or guaA recapitulates the xpt-pbuX-guaB-guaA deletion in vivo. In total, the data demonstrate that targeting the guanine riboswitch alone is insufficient to treat S. aureus infections but that inhibition of guaA or guaB could have therapeutic utility.
IMPORTANCE De novo guanine biosynthesis and purine salvage genes were reported to be regulated by a guanine riboswitch in Staphylococcus aureus. We demonstrate here that this is not true, because alternative promoter elements that uncouple the de novo pathway from riboswitch regulation were identified. We found that in animal models of infection, the purine salvage pathway is insufficient for S. aureus survival in the absence of de novo guanine biosynthesis. These data suggest targeting the de novo guanine biosynthesis pathway may have therapeutic utility in the treatment of S. aureus infections.
INTRODUCTION
Riboswitches are structured noncoding RNA elements located in the 5′ untranslated regions (5′-UTR) of a mRNA molecule. These molecular switches are present in many biosynthetic operons in bacteria. Riboswitches consist of a small-molecule-binding aptamer and an expression platform that together control gene expression in cis by directly binding to small molecules. The riboswitch is one example of negative feedback that, in some cases, explains how the end product of a biosynthetic or nutrient salvage operon can directly inhibit its own expression. One of the best characterized are the purine riboswitches that control enzymes involved in de novo purine biosynthesis, nucleotide metabolism, and nucleotide transport. Ligand binding by the aptamer domain transduces information about nutrient concentration to the expression platform via conformational changes associated with the ligand bound state (1). Guanine binding to its cognate riboswitch causes transcriptional attenuation by formation of an intrinsic terminator (2). Thus, elevated cellular concentrations of nutrients will shut down expression of the cognate biosynthetic operon.
In the model Gram-positive bacteria Bacillus subtilis, expression of the two-gene purine salvage operon xpt-pbuX encoding xanthine phosphoribosyltransferase (xpt) and xanthine permease (pbuX) is tightly regulated by guanine concentration (1, 3, 4). Transcriptional regulation of purine biosynthesis by guanine has been linked to the presence of a guanine-binding riboswitch in the 5′-UTR, by the GTP-binding LacI-type repressor CodY, and the regulator PurR (4–6). In Staphylococcus aureus, the riboswitch at the 5′-UTR of the mRNA consisting of the four-gene operon xpt-pbuX-guaB-guaA (henceforth referred to as xpt-riboswitch) has been reported to regulate the expression of these genes in response to guanine (7, 8). Both guaB and guaA, which encode inosine-5′-monophosphate dehydrogenase and GMP synthetase, respectively, are required for de novo biosynthesis of guanine nucleotides.
Crystal structures of riboswitches bound to small-molecule nutrients and their analogs ignited great interest in the possibility of identifying selective and potent molecules that would shut off essential gene expression in pathogens (3, 4). Many high-affinity riboswitch-binding purine and lysine analogs have been discovered (3, 9), and in silico modeling efforts have expanded the arsenal of tool compounds (10). In some cases, biochemical and structural information about riboswitches and their cognate ligands is far more advanced than our knowledge of the underlying pathogen biology being targeted. Two encouraging advances in the field came with identification of the flavin mononucleotide (FMN) riboswitch as the target for the natural antibiotic roseoflavin (11), and the identification of 2,5,6-triaminopyrimidin-4-one (PC1) that bound the xpt-riboswitch and was bactericidal to S. aureus in vivo (7). These studies showed that the riboswitches have potential as targets of antibiotics, and that in certain infection models, ligand analogs can kill bacterial pathogens.
However, many large hurdles exist to developing antibiotics that target the riboswitch. These include an incomplete understanding of what genes are essential for individual pathogens in vivo, the difficulty in parsing on- and off-target effects of lead compounds, the cytoplasmic location of the target, and lack of sufficient validation and/or commercial availability for many published analogs. Nevertheless, we set out to test the hypothesis that a riboswitch could be a good therapeutic target. We focused on the purine riboswitches in S. aureus because they were predicted to regulate two essential gene clusters, the xpt-pbuX-guaB-guaA and nrdI-nrdE-nrdF operons (7, 12, 13).
MATERIALS AND METHODS
Compounds.
4-Hydroxy-2,5,6-triaminopyrimidine sulfate (PC1), guanine, adenine, hypoxanthine, xanthine, guanosine, 2-aminopurine, 2′-deoxyguanosine, 6-thioguanine, 2,4-diaminopyrimidine, 2,4,6-triaminopyrimidine, 2,6-diaminopurine, 2,4,5,6-tetraaminopyrimidine, 2-nitrophenyl β-d-galactopyranoside, and all common chemical reagents were obtained from Sigma. 2-Acetamido-6-hydroxypurine was obtained from TCI. The identity and purity of PC1 were verified in-house by liquid chromatography (LC) and mass spectrometry (MS). PC1 stock solutions (2 mg/ml) required 0.03 N NaOH and 1.5 mM dithiothreitol (DTT) to promote solubility and prevent oxidative self-condensation (7, 8). All other compounds were made as 100 mM stocks in 0.1 N NaOH.
Construction of pIMC85.
The parental vector pIME6 was constructed by splicing by overhang extension PCR (SOE PCR; with primers IM202/IM205) joining the Pcp25-ermB marker (amplified with primers IM202/IM203 from pFX3EM) (57) to the partial replicon (repB; amplified with primers IM204/IM205) of pVE6007 (58). The SOE PCR product was gel extracted, phosphorylated with polynucleotide kinase, and self-ligated. The ligation was used to transform DC10B-R (EC10B [58] with the dcm gene deleted), and transformants were selected on L agar containing 200 μg/ml of erythromycin. DC10B-R supplies the RepA in trans, essential for plasmid replication. The soxR bidirectional transcription terminator was cloned as a double-stranded oligonucleotide into the unique BglII/EcoRI sites. The multiple-cloning site (MCS) was inserted between EcoRI and HindIII sites as a double-stranded oligonucleotide. To improve selection in diverse S. aureus strains, the Pcp25-ermB marker was exchanged for Phelp-cat (with an internal NcoI site deleted) amplified from pIMAY (with primers IM291/IM307/IM308/IM292) and was cloned into the unique SphI/NcoI sites, creating pIMC6. Genomic DNA was isolated from purified phage 85, and attP (amplified using primers IM285/IM286 and BglII/SphI restriction sites) and int (amplified using primers IM287/IM288 and NcoI/PstI restriction sites) were cloned to create pIMC85. The MCS is flanked by soxR and tonB transcription terminators, and phage 85 integrase is cotranscribed with the cat gene from the Phelp promoter. The plasmid cannot replicate in S. aureus; therefore, upon electroporation of the plasmid into the target strain, production of the Int stimulates stable plasmid integration between convergent genes rpmF and isdB (59). Transformants can be selected on brain heart infusion (BHI) agar with 10 μg/ml of chloramphenicol and screened by colony PCR with IM289/IM290.
Cloning.
Clean unmarked deletions in S. aureus were generated by homologous recombination using the pIMAY vector (14), and stable integration between the isdB-rpmF phage 85 att site was achieved using the pIMC85 vector. For ease of genetic manipulation, we used as genetic background a strain in which the restriction modification enzymes have been deleted; this strain is indistinguishable from the parental wild-type (WT) strain in mouse infection models (Table 1) (14). Transcriptional reporter constructs were generated first by PCR cloning promoter fragments into the B. subtilis integration vector pDG1661 using EcoRI/BamHI sites upstream of lacZ and were stably integrated into the amyE locus of B. subtilis (1A771) as previously described (Bacillus Genetics Stock Center) (4). These fusion constructs were subcloned for integration into S. aureus by digestion with PflF1/EcoRI followed by Klenow fill-in and blunt-end ligation into SmaI-digested pIMC85, followed by stable integration.
TABLE 1.
Bacterial species and strain | Strain designationa | Relevant genotype or other informationb | Reference or source |
---|---|---|---|
S. aureus NRS384 | WT | ΔhsdR ΔsauUSI | 14 |
B. subtilis 1A771 | EK1 | amyE::pDG1661-B. subtilis xpt(−305)-lacZ | This workc |
B. subtilis 1A771 | EK2 | amyE::pDG1661-S. aureus xpt(−452)-lacZ | This work |
S. aureus NRS384 | EK3 | ΔhsdR ΔsauUSI ϕ85att::pIMC85-S. aureus xpt(−452)-lacZ | This work |
S. aureus NRS384 | EK4 | ΔhsdR ΔsauUSI ϕ85att::pIMC85-S. aureus pbuX(−568)-lacZ | This work |
S. aureus NRS384 | EK5 | ΔhsdR ΔsauUSI ϕ85att::pIMC85-S. aureus guaB(−112)-lacZ | This work |
S. aureus NRS384 | EK6 | ΔhsdR ΔsauUSI ϕ85att::pIMC85-S. aureus guaA(−414)-lacZ | This work |
S. aureus NRS384 | EK7 | ΔhsdR ΔsauUSI ϕ85att::pIMC85-S. aureus guaA(−764)-lacZ | This work |
S. aureus NRS384 | EK8 | ΔhsdR ΔsauUSI Δxpt-pbuX | This work |
S. aureus NRS384 | EK9 | ΔhsdR ΔsauUSI pbuX::TnERM | This work |
S. aureus NRS384 | EK10 | ΔhsdR ΔsauUSI Δxpt-pbuX-guaB-guaA | This work |
S. aureus NRS384 | EK11 | ΔhsdR ΔsauUSI Δxpt-pbuX-guaB-guaA ϕ85att::pIMC85-xpt-pbuX-*guaB-guaA | This work |
S. aureus NRS384 | EK12 | ΔhsdR ΔsauUSI Δxpt-pbuX-guaB-guaA ϕ85att::pIMC85-xpt-pbuX-guaB-*guaA | This work |
S. aureus NRS384 | EK13 | ΔhsdR ΔsauUSI ΔguaB | This work |
S. aureus NRS384 | EK14 | ΔhsdR ΔsauUSI Δxpt-pbuX-guaB-guaA ϕ85att::pIMC85-xpt-pbuX-guaB-guaA | This work |
S. aureus NRS384 | EK15 | ΔhsdR ΔsauUSI ϕ85att::pIMC85-S. aureus nrdI(−218)-lacZ | This work |
B. subtilis 1A771 | EK16 | amyE::pDG1661-S. aureus nrdI(−218)-lacZ | This work |
K. pneumoniae subsp. pneumoniae Trevisan | ATCC 132 | ATCC | |
E. faecalis OG1RF | ATCC 47077 | ATCC | |
E. coli | Max Efficiency DH5α competent cells | Invitrogen | |
S. epidermidis Evans | ATCC 14990 | ATCC |
Strain designations used in this study.
The relevant genotype is given for the S. aureus and B. subtilis strains. An asterisk indicates introduction of an engineered stop codon in the gene. For the other species, the ATCC strain or product name is given.
Reproduction of strain originally reported in Mandal et al. (4) and studied here.
Miller assay.
Transcriptional reporter strains in B. subtilis were back diluted 1:100 from overnight cultures and grown to log phase in 1× Bacillus medium [14 g/liter K2HPO4, 6 g/liter KH2PO4, 2 g/liter (NH4)2SO4, 1 g/liter Na3 citrate·2H2O, 1 g/liter yeast extract, 0.2g/liter Casamino Acids, 0.5% (wt/vol) glucose], optical density at 600 nm was measured, and 1 ml of cells pelleted and lysed in 1 ml of 1× Z-buffer plus 40 μl chloroform and 20 μl of 0.1% SDS, followed by the addition of 100 μl of chromogenic substrate o-nitrophenyl-β-d-galactopyranoside (ONPG) (4 mg/ml in Z-buffer) per sample. The time of reaction was recorded, stopped with 200 μl of 1 M Na2CO3, particulates were quickly spun out, absorbance at 420 nm was measured, and Miller units were calculated as described previously (15). Assays in S. aureus were performed as described below, but the specific growth medium used (tryptic soy broth, Mueller-Hinton II broth, or chemically defined medium [CDM]) is indicated in figure legends.
Chemically defined medium for growth of S. aureus.
Chemically defined medium was formulated as previously described (16) for ZMB2 with the intentional exclusion of adenine, guanine, and xanthine.
Quantitative reverse transcription-PCR (qRT-PCR).
Custom TaqMan gene expression assays were obtained from Applied Biosystems (Life Technologies) as primer and 6-carboxyfluorescein (FAM)/minor groove binder (MGB)-nonfluorescent quencher (NFQ) reporter/quencher probe sets. First-strand synthesis for RT-PCR was performed using SuperScript III reverse transcriptase (Invitrogen). Analysis of relative gene expression data was performed using Applied Biosystems software and the 2−ΔΔCT method (17, 18).
Northern blotting.
Northern blotting was performed by classic methods (19). In brief, total RNA was harvested from log-phase cultures using the TRIzol method (Ambion), size separated by denaturing PAGE, overnight capillary transferred to nylon membranes, UV cross-linked, and processed using the NorthernMax blotting kit (Life Technologies). Probe template DNA was PCR amplified off the pIMC85-xpt-guaA complementation plasmid (for guaA and guaB) or S. aureus genomic DNA (for rrsA), gel extracted, and radioactively labeled using random hexamers, [α-32P]dCTP, and Klenow fragment to yield 250- to 500-bp DNA probes for the detection of guaB, guaA, and rrsA transcripts.
5′ rapid amplification of cDNA ends (5′-RACE).
Mapping the transcriptional start site of guaB was performed essentially as described by the manufacturer of the kit (catalog no. 18374-058; Invitrogen). In brief, we harvested total RNA from log-phase cultures, performed first-strand synthesis (Invitrogen), added a homopolymeric tail using terminal deoxynucleotidyltransferase, performed sequential nested PCRs, and TA-cloned products into the TOPO vector for sequence identification.
Water-LOGSY NMR.
The direct binding interaction of guanine/adenine with the riboswitch was monitored using the water-LOGSY (water-ligand observed via gradient spectroscopy) method first described by Dalvit et al. (20). The inherent low density of protons in RNA macromolecules makes ligand binding detection using the bulk solvent water polarization more amenable than direct proton polarization using saturation transfer difference (STD) nuclear magnetic resonance (NMR) (21). All NMR experiments were performed on a Bruker Avance 600-MHz spectrometer using a 5-mm TXI cryoprobe set to the previously calibrated temperature of 284 K. Samples were measured in 3-mm NMR tubes (Wilmad, MA, USA) with a sample volume of 180 μl. The phosphate-buffered saline (PBS) solution contained 5% 2H2O and was adjusted to pH 7.2 using a standard glass electrode with no correction for deuterium isotope effects. The guanine riboswitch was at a concentration of 10 μM, and the ligands were added from stock solutions to a concentration of 500 μM.
Transmission electron microscopy.
All samples were first fixed in modified Karnovsky's fixative (2% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer [pH 7.2]) and then postfixed in 1% aqueous osmium tetroxide for 2 h followed by incubation in 0.5% uranyl acetate for 2 h. The samples were then dehydrated through a series of ethanol solutions (50%, 70%, 90%, 95%, and 100%) followed by propylene oxide (each step was for 15 min) and embedded in Eponate 12 (Ted Pella, Redding, CA). Ultrathin sections (80 nm) were cut with an Ultracut microtome (Leica), stained with 0.2% lead citrate, and examined in a JEOL JEM-1400 transmission electron microscope (TEM) at 120 kV. Digital images were captured with a GATAN Ultrascan 1000 charge-coupled-device (CCD) camera. Quantification of morphological structures was performed manually in Microsoft PowerPoint by scoring for the presence of normal or abnormal septum on three 2,000× fields from each sample excluding cells with a diameter of <0.75 μm to avoid plane-of-sectioning artifacts. Quantification of external matrix thickness was performed on at least 12 independent 40,000× images by drawing a line between the cell membrane and the outermost staining of the cell wall, at two places on each cell. The average length was converted to nanometer values based on the proportion to the index included on each image. Data are presented as means ± standard errors of the means (SEM) for all TEM graphical representations.
Testing the virulence of bacterial mutants in mouse infection models.
For mouse bacteremia model, 7-week-old A/J female mice (Jackson Lab) were infected through tail vein injection with 2E6 CFU different bacterial strains prepared from tryptic soy broth (TSB) log-phase culture. At days 1 and 3 postinfection, kidneys from infected mice were collected and homogenized for CFU determination on blood agar plates. For a neutropenic thigh infection model, neutropenia in 6-week-old CD1 female mice (Charles River Laboratory) was induced by injecting the mice with 150 mg of cyclophosphamide/kg of body weight and 100 mg of cyclophosphamide/kg intraperitoneally (i.p.) at days −5 and −2, respectively. At day 0, mice were inoculated with 50 μl bacteria per mouse containing 2E5 CFU in the thigh muscle. At 24 h postinfection, thigh muscle was collected and homogenized for CFU determination on blood agar plates.
RESULTS
S. aureus contains a guanine-responsive xpt-riboswitch.
De novo guanine biosynthesis creates sufficient nucleotides to support fundamental cellular processes, and bacteria also have the ability to salvage nutrients from the environment to supplement the de novo pathway (Fig. 1a). Interestingly, in S. aureus, the xpt-pbuX-guaB-guaA operon is a cluster of two salvage pathway genes (xpt and pbuX) and two de novo biosynthetic genes (guaB and guaA) that are regulated by a guanine riboswitch (Fig. 1b) (7). Primary sequence alignments of the minimal aptamer domain of the xpt-riboswitch from B. subtilis and S. aureus revealed high overall conservation and complete conservation of nucleotides that define the guanine-binding riboswitch aptamer (Fig. 1c) (4, 22). Secondary structure prediction of the S. aureus xpt-aptamer domain revealed similar stem-loop architecture as that found in B. subtilis (Fig. 1d). To determine whether the predicted S. aureus riboswitch functioned similar to the B. subtilis riboswitch, we first tested it in B. subtilis where the function was well characterized (4).
To test whether the S. aureus xpt-riboswitch was responsive to guanine, we fused the xpt-riboswitch upstream of lacZ to report the effects of purine ligands and analogs on gene expression as described previously (4). Reporters were stably integrated into the amyE locus of B. subtilis (Table 1). Both B. subtilis (EK1) and S. aureus (EK2) xpt-5′-UTR-riboswitch lacZ reporters were completely turned off by guanine at 250 μM (Fig. 2a and b, respectively), confirming published B. subtilis data (3, 4), and indicating that the S. aureus xpt-leader sequence is guanine responsive. Because the B. subtilis riboswitch binds other purines with different affinities in vitro (3, 4), we tested hypoxanthine, adenine, and xanthine in the reporter assay. None of the other purines were as potent as guanine (Fig. 2c and d). Because both purine and pyrimidine analogs are capable of forming the proper network of hydrogen bonds to drive ligand-aptamer complex formation (3, 7, 23), a variety of purine and pyrimidine analogs were tested for their effect on reporter activity. Only 2-acetamido-6-hydroxypurine was as potent as guanine, suggesting that the xpt-riboswitch binds purine but not pyrimidine analogs (see Fig. S1a to d in the supplemental material).
The reporter system showed that in B. subtilis, the S. aureus xpt-riboswitch behaves similarly to the B. subtilis xpt-riboswitch, but this heterologous system may not accurately reflect the compound accessibility or the repertoire of transcriptional activators and repressors in S. aureus. Therefore, we stably integrated the S. aureus xpt(−452)-riboswitch reporter (an xpt riboswitch reporter construct starting at position −452 from the translational start site fused to the lacZ gene) into the isdB-rpmF phage 85 att site of NRS384, a virulent clinical isolate of S. aureus, to generate strain EK3 and tested the responses to natural purines and purine analogs. As expected, the S. aureus xpt-riboswitch reporter activity was strongly repressed in response to guanine (Fig. 2e). Interestingly, guanosine, 2′-deoxyguanosine, and 2-acetamido-6-hydroxypurine were equally effective at repression of reporter gene expression, whereas adenine significantly increased reporter expression (Fig. 2e). In contrast to the activity in B. subtilis, the S. aureus stable reporter strain had a modest but significant response to hypoxanthine, xanthine, and 2-aminopurine (Fig. 2e). While 2-acetamido-6-hydroxypurine has been shown biochemically to directly bind the guanine riboswitch (3), the other active compounds may be converted to guanine in the cell or may affect the balance of activators and repressors on the xpt promoter. Interestingly, we found that the B. subtilis xpt-riboswitch reporter was completely inactive in S. aureus (see Fig. S2 in the supplemental material). This observation emphasizes the need to interpret reporter data with caution, as small-molecule metabolites may have pleiotropic effects on the activity of transcriptional activators and repressors independent of the riboswitch, and heterologous systems may not accurately reflect the normal repertoire of regulators (24).
Confident that the S. aureus xpt-riboswitch was responsive to guanine in vivo, we then wanted to show directly whether guanine binding to the aptamer could explain this regulation. We used water-LOGSY NMR spectra to measure direct binding of purified RNA aptamers to the natural purines guanine and adenine (Fig. 2f). Both the B. subtilis and S. aureus xpt-riboswitch aptamers bound guanine but not adenine, 2-aminopurine, nor glucose (Fig. 2f and data not shown). These data confirm that the xpt-riboswitch from S. aureus directly bound ligands and repressed gene expression similarly to its Bacillus xpt-riboswitch orthologue (4, 22).
Repression of xpt, pbuX, guaB, and guaA expression by guanine.
We then asked whether endogenous transcripts for xpt, pbuX, guaB, and guaA were reduced when S. aureus was grown in the presence of exogenous guanine. S. aureus grown in chemically defined medium (CDM) supplemented with 1 mM guanine led to a significant reduction of all four transcripts as measured by qRT-PCR, but we observed a surprising difference in the extent of guanine repression between xpt-pbuX and guaB-guaA (Fig. 3a). While there was an ∼5-fold repression of xpt (0.29 ± 0.01, P < 0.001) and pbuX (0.22 ± 0.004, P < 0.001) in the presence of guanine, guaB (0.54 ± 0.09, P = 0.014) and guaA (0.62 ± 0.08, P = 0.015) message were reduced only ∼2-fold compared to untreated S. aureus cultures (Fig. 3a). The extent of repression of guaB did not differ significantly from guaA (P = 0.33), but it was significantly different from xpt (P = 0.01) and pbuX (P = 0.004). Using fourfold-less guanine (250 μM), there was significant repression of xpt (to 0.26 ± 0.09 of untreated, P = 0.008) and pbuX (0.19 ± 0.07, P = 0.004), whereas guaB and guaA transcription was not affected by this concentration of guanine (Fig. 3b).
In log-phase S. aureus, Northern blots using probes specific for guaB and guaA RNA showed an abundance of a 3-kb message that corresponds to a major guaB-guaA bicistronic transcript, a 2-kb message corresponding to guaA message (Fig. 3c and d), and an extremely faint 5.2-kb message, visible only on very overexposed blots, that corresponds to the previously described xpt-pbuX-guaB-guaA transcript (Fig. 3c) (7). Neither guaB nor guaA message was detected in RNA extracted from S. aureus Δxpt-guaA that confirmed probe specificity. RNA from the S. aureus Δxpt-pbuX internal deletion retained the guaB-guaA alternative promoter and both the 3-kb guaB-guaA message and the 2-kb guaA message (Fig. 3c). Ethidium bromide staining and reprobing blots for ribosomal 16S RNA (rrsA) show equal loading of total RNA (Fig. 3c). Together, these results suggest the presence of alternative promoters that drive endogenous expression of guaB and guaA genes independent of the xpt-pbuX promoter and the xpt-riboswitch in S. aureus.
Identification of alternative promoters for guaB and guaA.
To identify whether alternative promoters exist for guaB and/or guaA that are separate from the xpt riboswitch-controlled promoter, we constructed promoter-lacZ fusions by cloning regions upstream of each translational start site for S. aureus pbuX(−568) (EK4), guaB(−112) (EK5), and guaA(−414 and −764) (EK6 and EK7), and stably integrated these reporters into the isdB-rpmF phage 85 att site of S. aureus to directly compare promoter activity against xpt(−452) (EK3) (Fig. 1b and Table 1). While the xpt(−452) reporter strain was active and repressed by guanine, we failed to detect β-galactosidase activity from the pbuX(−568) reporter, suggesting the absence of an independent pbuX promoter within the test region. Consistent with the qRT-PCR results, the guaB(−112) reporter (EK5) was strongly active and was not regulated by guanine (Fig. 3d). Interestingly, the guaA(−764) reporter (EK7) was much stronger than either guaB or xpt promoters and not regulated by guanine, whereas the guaA(−414) reporter (EK6) was not active in S. aureus, thus locating an additional functional guanine-independent promoter for guaA between positions −764 and −414 (Fig. 3d). The presence of an alternative guaA promoter located within the guaB open reading frame is supported by the observation of a 2.0-kb guaA message that was detected by both guaA- and guaB-specific probes by Northern blotting (Fig. 3c). Together, our data suggest that the polycistronic xpt-pbuX-guaB-guaA message described previously (7) is a minor species in S. aureus, whereas the guaB-guaA(−112), and guaA(−764) alternative promoters are functionally dominant in S. aureus during active growth.
We then sought to identify the transcriptional start site of the alternative promoter in front of the major guaB-guaA bicistronic operon by 5′-RACE PCR. This method identified a single transcriptional start site located 31 bases upstream of the guaB start codon (Fig. 3e; see Fig. S3 in the supplemental material). This promoter site is predicted computationally with high confidence by bacterial sigma70 promoter recognition software (25).
Contributions of purine salvage and de novo guanine biosynthesis on growth in defined medium and human serum.
Nutritional requirements for the growth of S. aureus in human serum and during infection are largely unexplored, but evidence suggests that many bacterial pathogens absolutely require de novo nucleotide biosynthesis for virulence (26–34). To determine the importance of de novo guanine biosynthesis and purine salvage to the growth and virulence of S. aureus, we generated an unmarked clean deletion of xpt-pbuX (EK8; Δxpt-pbuX), a strain in which xpt-pbuX-guaB-guaA genes were deleted (EK10; Δxpt-guaA), introduced stop codons in guaB (EK11; guaB-KO [guaB knocked out]) or guaA (EK12; guaA-KO), and generated a strain pbuX::Tn (EK9), in which the pbuX locus containing a transposon insertion was transduced into strain NRS384 (Table 1).
Growth in tryptic soy broth (TSB) revealed a severe growth defect of Δxpt-guaA, guaB-KO, and guaA-KO strains (Fig. 4a) characterized by an extended lag phase and achievement of about half the cell density (in 96-well format) as that of the wild-type (WT) strain after 18 h, whereas no significant defects were observed in either the Δxpt-pbuX (Fig. 4a) or pbuX::Tn strain (see Fig. S4a in the supplemental material). Growth in chemically defined medium lacking purines shows that Δxpt-guaA, guaB-KO, and guaA-KO strains are guanine auxotrophs, whereas the purine salvage pathway mutants have no growth defect (Fig. 4b; see Fig. S4b). With the exception of guanine and guanosine, the other natural purines cannot reverse this defect, but xanthine does rescue growth of the guaB-KO strain, as expected from the order of steps in guanine biosynthesis (Fig. 4c and 1a). We suspect that guanine and guanosine are able to support growth of the knockout strains because they are efficiently imported by a nucleobase transporter and can be converted into essential guanine derivatives (Fig. 1a) (35).
We then asked whether de novo purine biosynthesis is required for growth of S. aureus in human serum where the concentration of free guanine is not detected (36, 37) and may more accurately reflect in vivo conditions during an infection (26, 38). To test this, we compared growth of the guanine auxotroph Δxpt-guaA to the guanine prototrophic WT, Δxpt-pbuX, and isogenic complemented (COMP; EK14) strains in 100% heat-inactivated human serum. Interestingly, the Δxpt-guaA strain completely failed to grow in human serum and actually lost CFU over time, whereas all of the prototrophic strains achieve 3 log units of growth in 24 h (Fig. 4d). As expected, the Δxpt-guaA failure to proliferate is completely reversed by the addition of exogenous guanine. Functional guaB or guaA is individually essential for growth in human serum, as shown by the complete growth failure of guaB-KO and guaA-KO strains (Fig. 4e). Growth of the guaB-KO strain was rescued by the addition of exogenous xanthine, whereas growth of the guaA-KO strain was not rescued (Fig. 4e), as predicted by the sequence of the purine biosynthetic pathway in S. aureus (Fig. 1a) and as observed in Fig. 4c. As a control, supplementation of serum with adenine did not restore growth of any mutant strain (Fig. 4e). Together, these results indicate that human serum does not contain sufficient free nucleotides to support growth of S. aureus in the absence of the de novo guanine biosynthetic pathway.
Effects of xpt, pbuX, guaB, and guaA on virulence of S. aureus in vivo.
To evaluate the requirement of the purine biosynthetic pathway during infection, we tested the WT, Δxpt-pbuX, and pbuX::Tn strains for virulence in a mouse bacteremia model by intravenous injection of early log-phase bacteria (2 × 106 CFU/mouse) and enumerated bacteria from the kidneys at 1 and 3 days postinfection. Although the purine salvage pathway-defective Δxpt-pbuX and pbuX::Tn mutants exhibited a marginal but significant reduction in kidney colonization on day 1, by day 3 they were not different from the wild-type (Fig. 5a) (P = 0.84 and P = 0.69, respectively). In contrast, the Δxpt-pbuX-guaB-guaA strain had a 2-log-unit reduction in kidney colonization on day 1 (Fig. 5b) (P = 0.0079), and infection was completely cleared by all mice on day 3 (Fig. 5b) (P = 0.0075). The virulence of the complemented strain was identical to that of the WT on both day 1 (Fig. 5b) (P = 1.0) and day 3 (Fig. 5b) (P = 1.0), demonstrating that the phenotype observed in the knockout was specific to deletion of xpt-pbuX-guaB-guaA and not a result of an unidentified mutation. Like the Δxpt-pbuX-guaB-guaA strain, the guaB-KO and guaA-KO strains were significantly reduced on day 1 (Fig. 5c) (P = 0.0079 and P = 0.0117, respectively), and completely cleared by day 3 (Fig. 5c) (P = 0.0097).
We then tested COMP, Δxpt-pbuX, Δxpt-pbuX-guaB-guaA, guaB-KO, and guaA-KO strains in the neutropenic thigh model of infection, where 2 × 105 bacteria were injected into one thigh muscle and CFU were enumerated 24 h later. In this model, the Δxpt-pbuX-guaB-guaA (P = 0.0079), guaB-KO (P = 0.0079), and guaA-KO (P = 0.0079) strains were severely attenuated for virulence, whereas the Δxpt-pbuX strain was not (P = 0.0556) (Fig. 5d). Treatment of COMP-infected mice with vancomycin (P = 0.0079) served as a control for inhibition of bacterial growth (Fig. 5d). Together, these data demonstrated that guaB and guaA were individually essential for virulence of S. aureus in vivo, whereas xpt and pbuX were dispensable. Interestingly, when we genotyped bacteria recovered from the kidneys of mice infected with guaB-KO and guaA-KO strains 24 h after infection (Fig. 5d), we identified the presence of stop codon revertants (Fig. 5d legend). This suggested that the log unit difference in bacterial growth observed between the Δxpt-pbuX-guaB-guaA clean deletion and guaB-KO or guaA-KO was the result of selection for reversion to guanine prototrophy in vivo. Reversion was not observed in the clean deletion ΔguaB strain (Fig. 5e). Together, these data highlight the importance of de novo guanine biosynthesis in the growth and survival of S. aureus during infection due to limitation of free guanine in vivo.
De novo guanine biosynthesis is required for growth, survival, and maintenance of normal cell morphology of S. aureus in medium lacking guanine.
We then compared the growth phenotype of the ΔguaB strain (EK13) to that of the Δxpt-guaA strain and found that growth of the ΔguaB strain in TSB was defective but not nearly as severe as that of the Δxpt-guaA strain (Fig. 6a). We then tested whether growth of the ΔguaB strain was defective in defined medium lacking guanine and found that guaB deletion phenocopies the strict guanine auxotrophy observed for the Δxpt-guaA strain (Fig. 6b). Strikingly, when we compared the growth and survival of the WT to the ΔguaB strain in shaking cultures, while there was no difference in recoverable CFU in rich broth (Fig. 6c), in CDM, loss of recoverable CFU was detected by day 2, and by day 6, no CFU could be recovered (Fig. 6d). When both WT and ΔguaB strains were grown in rich broth (TSB), there were no obvious differences between the strains in external matrix thickness and septation (Fig. 6e; see Fig. S5 in the supplemental material). At day 3 after transfer to medium lacking guanine, the ΔguaB cells displayed marked phenotypic abnormalities (Fig. 6e; see Fig. S5). The most striking difference was a pronounced lamellated thickening of the external matrix from ∼30 nm in input (both WT and ΔguaB strains) to ∼150 nm in the ΔguaB strain on day 3 (Fig. 6e and f; see Fig. S5). This defect occurred in 95% of the ΔguaB cells at day 3 and in none of the WT cells. A second defect seen in day 3 ΔguaB cells was abnormal division septa (Fig. 6e and g; see Fig. S5). In day 3 ΔguaB cells, we observed few (5%) morphologically normal trilamellar planes of cell division, whereas ∼50% of WT cell profiles at day 3 and ∼50% of the input WT and input ΔguaB cell profiles had morphologically normal division septae (Fig. 6g). Instead, division septae in day 3 ΔguaB cells, which were present at a frequency comparable to that of WT cells, were markedly thickened and only rarely trilaminar.
Bactericidal analog PC1 mode of action is independent of the guanine riboswitch.
The development of riboswitch-binding nucleotide analogs suggested that inhibition of expression of essential genes regulated by these gene regulatory elements may be possible (39). Based on the crystal structure of hypoxanthine bound to a guanine riboswitch (22), it was proposed that purine and pyrimidine analogs could also form a network of hydrogen bonds for proper complex formation between ligand and aptamer (7). A pyrimidine analog 2,5,6-triaminopyrimidin-4-one (PC1) was reported to kill S. aureus but not bacteria that lack guanine riboswitch control of guaA (7, 8). We tested the antibiotic potential of PC1 against S. aureus, Staphylococcus epidermidis, Bacillus subtilis, Klebsiella pneumoniae, Enterococcus faecalis, and Escherichia coli and confirmed that PC1 indeed kills Staphylococcus but not the other Gram-positive and -negative bacteria examined (see Fig. S6 in the supplemental material).
Since our data suggested that there were riboswitch-independent promoters for the essential guaA and guaB genes, we cultured WT S. aureus with 1 mM PC1 overnight in tryptic soy broth with or without 1 mM exogenous guanine. Although 1 mM guanine should recover bacterial growth in the absence of guaA and guaB (Fig. 4), we obtained no recoverable CFU in the presence of PC1, whether or not guanine was present (see Fig. S6b in the supplemental material). Supplementation of Mueller-Hinton broth with GMP, AMP, and guanine all failed to rescue S. aureus from the cytotoxic effects of PC1 (see Fig. S7). Importantly, failure of guanine to rescue cell viability demonstrated that the antibiotic activity of PC1 cannot result solely from inhibition of guanine biosynthesis. To determine whether endogenous xpt, pbuX, guaB, and guaA transcripts were affected by PC1, we performed qRT-PCR on RNA collected from log-phase S. aureus grown in tryptic soy broth in the presence of various amounts of PC1. Surprisingly, repression of endogenous gene expression was not observed for xpt, pbuX, guaB, nor guaA at any concentration (see Fig. S6c). We then tested whether PC1 influences reporter gene expression in B. subtilis carrying the B. subtilis xpt or S. aureus xpt reporter and found that PC1 did not alter reporter activity in either strain (see Fig. S6d). PC1 also failed to have any effect on the S. aureus xpt reporter stably integrated in S. aureus (see Fig. S6e).
Finally, to determine the whether PC1 toxicity required repression of the xpt-pbuX-guaB-guaA operon, we monitored the effects of 0.5 and 1 mM PC1 on the growth of WT and Δxpt-guaA strains in Mueller-Hinton broth (see Fig. S6f in the supplemental material). The susceptibility of theΔxpt-guaA strain to PC1 was indistinguishable from that of the WT, demonstrating that the bactericidal mode of action of PC1 is independent of the xpt-pbuX-guaB-guaA gene locus in S. aureus. Interestingly, PC1 was also cytotoxic to murine BALB/c peritoneal macrophages at the same concentration that it has activity against S. aureus despite the absence of purine riboswitches in mammalian cells (see Fig. S8). The identity and purity of PC1 were verified by analytical liquid chromatography-mass spectrometry (see Fig. S9).
The nrdIEF operon of S. aureus does not contain a guanine riboswitch in its 5′-UTR.
Bioinformatic analysis of S. aureus N315 for noncoding regulatory elements had predicted that a purine riboswitch was located in the 5′-UTR of the nucleotide reductase nrdI-nrdE-nrdF operon (12). Because the nrdI-nrdE-nrdF operon appeared to be essential in both B. subtilis and S. aureus from an absence of insertions from transposon libraries (40) (41) and an inability to generate targeted disruptions in the operon (13), we tested whether this region encodes a bona fide guanine riboswitch.
To determine the level of similarity between xpt and nrd 5′-leader sequences, we generated pairwise sequence alignments of the S. aureus nrd 5′-UTR and the S. aureus xpt 5′-UTR (see Fig. S10a in the supplemental material). There was considerable deviation from nucleotides conserved in guanine-binding riboswitch aptamers, and the predicted secondary structure of the nrd leader region fails to form the typical three-junction stem-loop structure (see Fig. S10b). These observations argue against a guanine-responsive riboswitch at the nrd promoter. To test this hypothesis experimentally, we performed qRT-PCR on RNA from S. aureus grown in CDM overnight in the presence or absence of 1 mM guanine and measured transcript abundance of nrdI, nrdE, and nrdF relative to the untreated controls. Exogenous guanine had no significant effect on transcript abundance of nrdI, nrdE, nor nrdF (see Fig. S10c), suggesting the absence of a guanine-responsive riboswitch in this promoter. In an additional experiment, we isolated RNA from log-phase cultures of S. aureus grown in TSB with various concentrations of exogenous guanine but found no evidence that guanine significantly affects expression of nrdI, nrdE, and nrdF (see Fig. S10d). Finally, we generated an S. aureus nrd transcriptional reporter strain by fusion of the nrd promoter(−218 from transcriptional start site) (42) to lacZ stably integrated in B. subtilis [nrd(−218) (EK16)] (see Fig. S10e), and S. aureus [nrd(−218) (EK15)] (see Fig. S10f). Reporter activity was mildly but significantly repressed by guanine and significantly increased by adenine in B. subtilis (see Fig. S10e). Treatment with hydroxyurea stimulates expression from this promoter (13, 43), and we observed an ∼16-fold induction of expression upon treatment (see Fig. S10e). In hydroxyurea-treated bacteria, there was a mild but significant reduction in reporter activity upon guanine treatment. In contrast, reporter activity in S. aureus was very low and not significantly altered by culture with guanine or adenine (see Fig. S10f). The S. aureus nrd promoter was not strongly active in a variety of culture conditions tested, including anaerobic growth, log, nor in stationary phase (data not shown). In total, the data suggest that the nrd 5′-UTR of S. aureus does not contain a guanine riboswitch.
DISCUSSION
Here we demonstrate both in mouse infection models and in human serum, that guanine limitation constrains virulence of S. aureus and that the purine salvage pathway was dispensable. Although we ruled out the guanine riboswitch as a potential antibiotic target in S. aureus, this study provides several new insights into the regulation of the xpt, pbuX, guaB, and guaA genetic locus. We confirm the existence of a bona fide guanine riboswitch in the S. aureus xpt-5′-UTR that tightly regulated the expression of the purine salvage pathway enzymes xpt and pbuX. However, the proposed four-gene operon can be separated into at least three independent transcriptional units, the major species being a 3.0-kb bicistronic guaB-guaA operon and alternative 2-kb guaA transcript, and a minor 5.2-kb polycistronic xpt-pbuX-guaB-guaA four-gene operon. Most importantly, guaB and guaA were each individually essential for virulence and growth of S. aureus in vivo, and therefore constitute two potential antibiotic targets. Finally, the loss of guaB is bactericidal under conditions where guanine is limiting and is associated with profound morphological abnormalities in cell morphology. De novo guanine biosynthesis has been shown to be important for virulence of many bacterial pathogens (26–34) but has never been demonstrated for S. aureus. The data presented here show that the purine salvage pathway appears to be much less important than the de novo synthesis pathway during infection.
We are currently striving to identify the composition of the thickened external matrix in the ΔguaB cells as observed in the electron microscopy images and to understand why cell viability deteriorates in this strain. Previous work has shown that pharmacological inhibition of guaA in B. subtilis prevents peptidoglycan turnover and recycling (44), but the cause of this phenotype was never mechanistically explained. Cell wall thickening by ∼10 nm has been linked to vancomycin resistance in S. aureus and was characterized by TEM (45), but the morphology of those strains bear no resemblance to the severe morphological defects we observe. Instead, the morphology more closely resembled S. aureus treatment with chloramphenicol (46). Whatever the molecular mechanism, bacteria lacking guaB clearly have severe problems with cell division that results in loss of viability.
The vast majority of Firmicutes maintain xpt under direct riboswitch regulation typically in a two-gene operon with pbuX (47), but maintain guaB and guaA as separate genes, of which only a small subset are reported to be directly regulated by a purine riboswitch (47). In retrospect, the existence of complex regulation of guaB and guaA expression is not surprising, given the critical role that de novo guanine biosynthesis plays in bacterial growth and virulence.
Because the guanine riboswitch was reported to regulate the de novo synthesis pathway in S. aureus, we evaluated the feasibility of developing small-molecule drugs that bind the bacterial guanine riboswitch and prevent the expression of genes essential for the survival and virulence of S. aureus. Here we provide several lines of evidence to suggest that this approach will not be useful to treat S. aureus infection. First, the xpt-riboswitch exclusively regulated only the transcription of xpt and pbuX, and the Δxpt-pbuX strain was not defective in virulence in two murine infection models (Fig. 5a and d). Second, the guanine analog 2-acetamido-6-hydroxypurine strongly repressed riboswitch reporter activity but failed to alter growth in chemically defined and rich media (Fig. 2g; see Fig. S1 in the supplemental material). Third, individually, guaB and guaA were essential for virulence in vivo but were regulated by alternative promoters independent from control by the guanine riboswitch. Fourth, we found no evidence that the nrdIEF operon was controlled by a guanine riboswitch in S. aureus, suggesting that no essential genes were strictly controlled by a guanine riboswitch in S. aureus (see Fig. S10). Finally, the antibiotic activity of PC1, which was reported to have selectivity for the guanine riboswitch, appeared to result from effects independent of this target (see Fig. S6 to S8).
Similar to PC1, the antibiotic lysine analog S-(2-aminoethyl)-l-cysteine (AEC) binds the lysine riboswitch (9, 48, 49) but has also been clearly demonstrated to have other cellular targets (50), including being directly incorporated into proteins (51, 52). Surprisingly, high-affinity riboswitch ligand analogs do not always modulate transcription (3, 53, 54), which adds another layer of complexity to an already daunting challenge of developing antibiotics that target the riboswitch. However, two recent reports have identified small-molecule inhibitors targeting the riboflavin riboswitch that have in vivo activity against E. coli (55) and C. difficile (60).
Despite the shortfalls of the guanine riboswitch as an antibiotic target in S. aureus, it remains possible that guaB or guaA is regulated by this mechanism in other bacterial pathogens. The inability of guaB and guaA mutants to survive in vivo, in medium lacking guanine, and in human serum indicates that guanine is severely limiting and suggests that targeting these proteins may have therapeutic value for persistent bacterial infections.
Supplementary Material
ACKNOWLEDGMENTS
E.M.K. and M.-W.T designed all experiments, and E.M.K. executed all experiments and performed all data analysis with the following exceptions: C.D.A., M.R., and A.K.K. designed and executed transmission electron microscopy experiments; M.X., D.Y., J.K., and S.P. performed all in vivo infections and organ harvest; T.M. designed and performed waterLOGSY NMR of RNA aptamers; B.L. performed LC/MS analysis of purchased compounds to verify identity and purity; S.V.D. performed computational analysis of the USA300 (NRS384) genome; and I.R.M. constructed pIMC85.
Footnotes
Supplemental material for this article may be found at http://dx.doi.org/10.1128/JB.00051-16.
REFERENCES
- 1.Roth A, Breaker RR. 2009. The structural and functional diversity of metabolite-binding riboswitches. Annu Rev Biochem 78:305–334. doi: 10.1146/annurev.biochem.78.070507.135656. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Serganov A, Nudler E. 2013. A decade of riboswitches. Cell 152:17–24. doi: 10.1016/j.cell.2012.12.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kim JN, Blount KF, Puskarz I, Lim J, Link KH, Breaker RR. 2009. Design and antimicrobial action of purine analogues that bind guanine riboswitches. ACS Chem Biol 4:915–927. doi: 10.1021/cb900146k. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Mandal M, Boese B, Barrick JE, Winkler WC, Breaker RR. 2003. Riboswitches control fundamental biochemical pathways in Bacillus subtilis and other bacteria. Cell 113:577–586. doi: 10.1016/S0092-8674(03)00391-X. [DOI] [PubMed] [Google Scholar]
- 5.Brinsmade SR, Sonenshein AL. 2011. Dissecting complex metabolic integration provides direct genetic evidence for CodY activation by guanine nucleotides. J Bacteriol 193:5637–5648. doi: 10.1128/JB.05510-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Cho BK, Federowicz SA, Embree M, Park YS, Kim D, Palsson BO. 2011. The PurR regulon in Escherichia coli K-12 MG1655. Nucleic Acids Res 39:6456–6464. doi: 10.1093/nar/gkr307. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Mulhbacher J, Brouillette E, Allard M, Fortier LC, Malouin F, Lafontaine DA. 2010. Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways. PLoS Pathog 6:e1000865. doi: 10.1371/journal.ppat.1000865. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Ster C, Allard M, Boulanger S, Lamontagne Boulet M, Mulhbacher J, Lafontaine DA, Marsault E, Lacasse P, Malouin F. 2013. Experimental treatment of Staphylococcus aureus bovine intramammary infection using a guanine riboswitch ligand analog. J Dairy Sci 96:1000–1008. doi: 10.3168/jds.2012-5890. [DOI] [PubMed] [Google Scholar]
- 9.Blount KF, Wang JX, Lim J, Sudarsan N, Breaker RR. 2007. Antibacterial lysine analogs that target lysine riboswitches. Nat Chem Biol 3:44–49. doi: 10.1038/nchembio842. [DOI] [PubMed] [Google Scholar]
- 10.Daldrop P, Reyes FE, Robinson DA, Hammond CM, Lilley DM, Batey RT, Brenk R. 2011. Novel ligands for a purine riboswitch discovered by RNA-ligand docking. Chem Biol 18:324–335. doi: 10.1016/j.chembiol.2010.12.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Lee ER, Blount KF, Breaker RR. 2009. Roseoflavin is a natural antibacterial compound that binds to FMN riboswitches and regulates gene expression. RNA Biol 6:187–194. doi: 10.4161/rna.6.2.7727. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Geissmann T, Chevalier C, Cros MJ, Boisset S, Fechter P, Noirot C, Schrenzel J, Francois P, Vandenesch F, Gaspin C, Romby P. 2009. A search for small noncoding RNAs in Staphylococcus aureus reveals a conserved sequence motif for regulation. Nucleic Acids Res 37:7239–7257. doi: 10.1093/nar/gkp668. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Masalha M, Borovok I, Schreiber R, Aharonowitz Y, Cohen G. 2001. Analysis of transcription of the Staphylococcus aureus aerobic class Ib and anaerobic class III ribonucleotide reductase genes in response to oxygen. J Bacteriol 183:7260–7272. doi: 10.1128/JB.183.24.7260-7272.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Monk IR, Shah IM, Xu M, Tan MW, Foster TJ. 2012. Transforming the untransformable: application of direct transformation to manipulate genetically Staphylococcus aureus and Staphylococcus epidermidis. mBio 3:e00277–11. doi: 10.1128/mBio.00277-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Miller JH. 1972. Experiments in molecular genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. [Google Scholar]
- 16.Zhang G, Mills DA, Block DE. 2009. Development of chemically defined media supporting high-cell-density growth of lactococci, enterococci, and streptococci. Appl Environ Microbiol 75:1080–1087. doi: 10.1128/AEM.01416-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45. doi: 10.1093/nar/29.9.e45. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 25:402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
- 19.Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: a laboratory manual, 2nd ed Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. [Google Scholar]
- 20.Dalvit C, Pevarello P, Tato M, Veronesi M, Vulpetti A, Sundstrom M. 2000. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J Biomol NMR 18:65–68. doi: 10.1023/A:1008354229396. [DOI] [PubMed] [Google Scholar]
- 21.Mayer M, Meyer B. 1999. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew Chem Int Ed 38:1784–1788. doi:. [DOI] [PubMed] [Google Scholar]
- 22.Batey RT, Gilbert SD, Montange RK. 2004. Structure of a natural guanine-responsive riboswitch complexed with the metabolite hypoxanthine. Nature 432:411–415. doi: 10.1038/nature03037. [DOI] [PubMed] [Google Scholar]
- 23.Gilbert SD, Mediatore SJ, Batey RT. 2006. Modified pyrimidines specifically bind the purine riboswitch. J Am Chem Soc 128:14214–14215. doi: 10.1021/ja063645t. [DOI] [PubMed] [Google Scholar]
- 24.Belitsky BR, Sonenshein AL. 2013. Genome-wide identification of Bacillus subtilis CodY-binding sites at single-nucleotide resolution. Proc Natl Acad Sci U S A 110:7026–7031. doi: 10.1073/pnas.1300428110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Solovyev V, Salamov A. 2011. Automatic annotation of microbial genomes and metagenomic sequences, p 61–78. In Li RW. (ed), Metagenomics and its applications in agriculture, biomedicine and environmental studies. Nova Science Publishers, Hauppauge, NY. [Google Scholar]
- 26.Samant S, Lee H, Ghassemi M, Chen J, Cook JL, Mankin AS, Neyfakh AA. 2008. Nucleotide biosynthesis is critical for growth of bacteria in human blood. PLoS Pathog 4:e37. doi: 10.1371/journal.ppat.0040037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.McFarland WC, Stocker BA. 1987. Effect of different purine auxotrophic mutations on mouse-virulence of a Vi-positive strain of Salmonella dublin and of two strains of Salmonella typhimurium. Microb Pathog 3:129–141. doi: 10.1016/0882-4010(87)90071-4. [DOI] [PubMed] [Google Scholar]
- 28.Santiago AE, Cole LE, Franco A, Vogel SN, Levine MM, Barry EM. 2009. Characterization of rationally attenuated Francisella tularensis vaccine strains that harbor deletions in the guaA and guaB genes. Vaccine 27:2426–2436. doi: 10.1016/j.vaccine.2009.02.073. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Subashchandrabose S, Smith SN, Spurbeck RR, Kole MM, Mobley HL. 2013. Genome-wide detection of fitness genes in uropathogenic Escherichia coli during systemic infection. PLoS Pathog 9:e1003788. doi: 10.1371/journal.ppat.1003788. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Le Breton Y, Mistry P, Valdes KM, Quigley J, Kumar N, Tettelin H, McIver KS. 2013. Genome-wide identification of genes required for fitness of group A Streptococcus in human blood. Infect Immun 81:862–875. doi: 10.1128/IAI.00837-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Russo TA, Jodush ST, Brown JJ, Johnson JR. 1996. Identification of two previously unrecognized genes (guaA and argC) important for uropathogenesis. Mol Microbiol 22:217–229. doi: 10.1046/j.1365-2958.1996.00096.x. [DOI] [PubMed] [Google Scholar]
- 32.Morrow CA, Valkov E, Stamp A, Chow EW, Lee IR, Wronski A, Williams SJ, Hill JM, Djordjevic JT, Kappler U, Kobe B, Fraser JA. 2012. De novo GTP biosynthesis is critical for virulence of the fungal pathogen Cryptococcus neoformans. PLoS Pathog 8:e1002957. doi: 10.1371/journal.ppat.1002957. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Noriega FR, Losonsky G, Lauderbaugh C, Liao FM, Wang JY, Levine MM. 1996. Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine. Infect Immun 64:3055–3061. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Jewett MW, Lawrence KA, Bestor A, Byram R, Gherardini F, Rosa PA. 2009. GuaA and GuaB are essential for Borrelia burgdorferi survival in the tick-mouse infection cycle. J Bacteriol 191:6231–6241. doi: 10.1128/JB.00450-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Jensen KF, Dandanell G, Hove-Jensen B, Willemoes M. 18 August 2008, posting date Nucleotides, nucleosides, and nucleobases. EcoSal Plus 2013 doi: 10.1128/ecosalplus.3.6.2. [DOI] [PubMed] [Google Scholar]
- 36.Eells JT, Spector R. 1983. Purine and pyrimidine base and nucleoside concentrations in human cerebrospinal fluid and plasma. Neurochem Res 8:1451–1457. doi: 10.1007/BF00965000. [DOI] [PubMed] [Google Scholar]
- 37.Liu Z, Li T, Wang E. 1995. Simultaneous determination of guanine, uric acid, hypoxanthine and xanthine in human plasma by reversed-phase high-performance liquid chromatography with amperometric detection. Analyst 120:2181–2184. doi: 10.1039/an9952002181. [DOI] [PubMed] [Google Scholar]
- 38.Traut TW. 1994. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 140:1–22. doi: 10.1007/BF00928361. [DOI] [PubMed] [Google Scholar]
- 39.Blount KF, Breaker RR. 2006. Riboswitches as antibacterial drug targets. Nat Biotechnol 24:1558–1564. doi: 10.1038/nbt1268. [DOI] [PubMed] [Google Scholar]
- 40.Kobayashi K, Ehrlich SD, Albertini A, Amati G, Andersen KK, Arnaud M, Asai K, Ashikaga S, Aymerich S, Bessieres P, Boland F, Brignell SC, Bron S, Bunai K, Chapuis J, Christiansen LC, Danchin A, Debarbouille M, Dervyn E, Deuerling E, Devine K, Devine SK, Dreesen O, Errington J, Fillinger S, Foster SJ, Fujita Y, Galizzi A, Gardan R, Eschevins C, Fukushima T, Haga K, Harwood CR, Hecker M, Hosoya D, Hullo MF, Kakeshita H, Karamata D, Kasahara Y, Kawamura F, Koga K, Koski P, Kuwana R, Imamura D, Ishimaru M, Ishikawa S, Ishio I, Le Coq D, Masson A, Mauel C, et al. . 2003. Essential Bacillus subtilis genes. Proc Natl Acad Sci U S A 100:4678–4683. doi: 10.1073/pnas.0730515100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Fey PD, Endres JL, Yajjala VK, Widhelm TJ, Boissy RJ, Bose JL, Bayles KW. 2013. A genetic resource for rapid and comprehensive phenotype screening of nonessential Staphylococcus aureus genes. mBio 4:e00537–12. doi: 10.1128/mBio.00537-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Hartig E, Hartmann A, Schatzle M, Albertini AM, Jahn D. 2006. The Bacillus subtilis nrdEF genes, encoding a class Ib ribonucleotide reductase, are essential for aerobic and anaerobic growth. Appl Environ Microbiol 72:5260–5265. doi: 10.1128/AEM.00599-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Sinha NK, Snustad DP. 1972. Mechanism of inhibition of deoxyribonucleic acid synthesis in Escherichia coli by hydroxyurea. J Bacteriol 112:1321–1324. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Uratani B, Lopez JM, Freese E. 1983. Effect of decoyinine on peptidoglycan synthesis and turnover in Bacillus subtilis. J Bacteriol 154:261–268. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Cui L, Ma X, Sato K, Okuma K, Tenover FC, Mamizuka EM, Gemmell CG, Kim MN, Ploy MC, El-Solh N, Ferraz V, Hiramatsu K. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 41:5–14. doi: 10.1128/JCM.41.1.5-14.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Giesbrecht P, Kersten T, Maidhof H, Wecke J. 1998. Staphylococcal cell wall: morphogenesis and fatal variations in the presence of penicillin. Microbiol Mol Biol Rev 62:1371–1414. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Singh P, Sengupta S. 2012. Phylogenetic analysis and comparative genomics of purine riboswitch distribution in prokaryotes. Evol Bioinform Online 8:589–609. doi: 10.4137/EBO.S10048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Lu Y, Shevtchenko TN, Paulus H. 1992. Fine-structure mapping of cis-acting control sites in the lysC operon of Bacillus subtilis. FEMS Microbiol Lett 71:23–27. [DOI] [PubMed] [Google Scholar]
- 49.Sudarsan N, Wickiser JK, Nakamura S, Ebert MS, Breaker RR. 2003. An mRNA structure in bacteria that controls gene expression by binding lysine. Genes Dev 17:2688–2697. doi: 10.1101/gad.1140003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Ataide SF, Wilson SN, Dang S, Rogers TE, Roy B, Banerjee R, Henkin TM, Ibba M. 2007. Mechanisms of resistance to an amino acid antibiotic that targets translation. ACS Chem Biol 2:819–827. doi: 10.1021/cb7002253. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Hirshfield IN, Zamecnik PC. 1972. Thiosine-resistant mutants of Escherichia coli K-12 with growth-medium-dependent lysl-tRNA synthetase activity. I. Isolation and physiological characterization. Biochim Biophys Acta 259:330–343. [PubMed] [Google Scholar]
- 52.Di Girolamo M, Busiello V, Coccia R, Foppoli C. 1990. Aspartokinase III repression and lysine analogs utilization for protein synthesis. Physiol Chem Phys Med NMR 22:241–245. [PubMed] [Google Scholar]
- 53.Cressina E, Chen L, Moulin M, Leeper FJ, Abell C, Smith AG. 2011. Identification of novel ligands for thiamine pyrophosphate (TPP) riboswitches. Biochem Soc Trans 39:652–657. doi: 10.1042/BST0390652. [DOI] [PubMed] [Google Scholar]
- 54.Trausch JJ, Batey RT. 2014. A disconnect between high-affinity binding and efficient regulation by antifolates and purines in the tetrahydrofolate riboswitch. Chem Biol 21:205–216. doi: 10.1016/j.chembiol.2013.11.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Howe JA, Wang H, Fischmann TO, Balibar CJ, Xiao L, Galgoci AM, Malinverni JC, Mayhood T, Villafania A, Nahvi A, Murgolo N, Barbieri CM, Mann PA, Carr D, Xia E, Zuck P, Riley D, Painter RE, Walker SS, Sherborne B, de Jesus R, Pan W, Plotkin MA, Wu J, Rindgen D, Cummings J, Garlisi CG, Zhang R, Sheth PR, Gill CJ, Tang H, Roemer T. 2015. Selective small-molecule inhibition of an RNA structural element. Nature 526:672–677. doi: 10.1038/nature15542. [DOI] [PubMed] [Google Scholar]
- 56.Gruber AR, Bernhart SH, Lorenz R. 2015. The ViennaRNA web services. Methods Mol Biol 1269:307–326. doi: 10.1007/978-1-4939-2291-8_19. [DOI] [PubMed] [Google Scholar]
- 57.van Pijkeren JP, Morrissey D, Monk IR, Cronin M, Rajendran S, O'Sullivan GC, Gahan CGM, Tangney M. 2010. A novel Listeria monocytogenes-based DNA delivery system for cancer gene therapy. Hum Gene Ther 21:405–416. doi: 10.1089/hum.2009.022. [DOI] [PubMed] [Google Scholar]
- 58.Monk IR, Gahan CGM, Hill C. 2008. Tools for functional postgenomic analysis of Listeria monocytogenes. Appl Environ Microbiol 74:3921–3934. doi: 10.1128/AEM.00314-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Christie GE, Matthews AM, King DG, Lane KD, Olivarez NP, Tallent SM, Gill SR, Novick RP. The complete genomes of Staphylococcus aureus bacteriophages 80 and 80α—implications for the specificity of SaPI mobilization. Virology 407:381–390. doi: 10.1016/j.virol.2010.08.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Blount KF, Megyola C, Plummer M, Osterman D, O'Connell T, Aristoff P, Quinn C, Chrusciel RA, Poel TJ, Schostarez HJ, Stewart CA, Walker DP, Wuts PGM, Breaker RR. 2015. Novel riboswitch-binding flavin analog that protects mice against Clostridium difficile infection without inhibiting cecal flora. Antimicrob Agents Chemother 59:5736–5746. doi: 10.1128/AAC.01282-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.